Substitut	te for t	form 1449A/PTO (Replic	cation)	Comple	ete if Known
		TION DISCLOSU		Application Number	10/661,329
STAT	EME	NT BY APPLICA	NT	Filing Date	September 12, 2003
	/	CLAF 108		First Named Inventor	Allan L. Louderback
!		שַׁ משר,		Art Unit	
		DEC O 1 MING ST		Examiner Name	
Sheet	P.	1	4	Attorney Docket Number	ALLO01
		& IBADENTA	U.S. PATEN	IT DOCUMENTS	
Examiner	1	Document Number	Patent Date	No.	
Initials	e m	Number - kind code (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
An	01	4,305,871	12-15-81	Shanbrom	Abstract, Example 1, Claim 1
m	02	4,314,997	02-09-82	Shanbrom	Abstract, First paragraph following Description of Invention, Claim 1
~~	03	4,315,919	02-16-82	Shanbrom	Abstract, Claim 1
M	04	4,412,985	11-01-83	Shanbrom	Abstract, Claim 1
N	05	4,481,189	11-06-84	Prince	Abstract, See first paragraph of Discussion of Prior Art eighth paragraph of same section
M	06	4,591,505	05-27-86	Prince	Abstract, Division of 4,481,189
W	07	4,764,369	08-16-88	Neurath, et al.	See abstract, prior art discussion
M	ОВ	4,833,165	05-23-89	Louderback	See Details of Invention, Claim
M	09	4,909,940	03-20-90	Horowitz	Abstract, Background, Claim 1
w	10	5,094,960	03-10-92	Bonomo	Abstract, Claim 1
m	11	5,120,649	06-09-92	Horowitz, et al.	Abstract, Claim 1
<u></u>	12	5,186,945	02-16-93	Shanbrom	See Abstract, Claim 1
M	13	5,648,472	07-15-97	Gehringer, et al.	See Abstract, Claim 1
W	14	6,372,216	04-16-02	Piazza	See Abstract, See last paragraph before claims
M	15	6,468,733	10-22-02	Nur, et al.	See Abstract, Claim 1
N	16	6,514,987	02-04-2003	Cook, et al.	See Abstract, Claim 1

FC	REIGN PATEN	T DOCUMENTS	
None			
xaminer ignature	500	Date Considered	11/18/04
77			-//-

Substitute	Substitute for form 1449A/PTO (Replication)				Comple	te if Known	
1		TION DISC			Application Number	10/661,329	
STAFE	STATEMENT BY APPLICANT				Filing Date	10/661,329	
					First Named Inventor	Allan L. Louderback	
٠,					Art Unit		
1		Ž			Examiner Name		
Sheet	NL8	TEAL 2	o f	4	Attorney Docket Number	ALL001	
		OTHER	PR	OR ART - NON PAT	TENT LITERATURE DOC	CUMENTS	
Examiner Initials	#			journal, serial, symposium, i	TERS), title of the article (when catalog, etc.), date, page(s), voluor county where published		
Xh	01	AGER, A.; ANDERSON, SL; LOUDERBACK AL; MILHOUS, WK; Formaldehyde/Detergent Solution Prevents Blood Borne Transmission of (Plasmaodium) Infection in a Mouse Model, American Society of Tropical Medicine and Hygiene, Abstract Submission Form, Annual Meeting, 1991					
m	02	EHUD BEN-HUR, BERNARD HOROWITZ, Virus Inactivation in Blood, Editorial Review, AIDS 1996, 10:1183-1190, Rapid Science Publishers ISSN 0269-9370.					
M	03	CHEN, SX; HAMMOND, DJ; LANG, JM; LEBING, WR; Purification of α_1 Protinase Inhibitor from Human Plasma Fraction IV-1 by Ion Exchange Chromatography; Vox Sanguinis, 1998: 74(4): 232-241.					
N	04	CHEN, SX; HAMMOND, DJ; KLOS, AM; WOOD, DW; WYDICK, JE; LEBING, WR; Chromatography Purification of human α, Proteinase Inhibitor from Dissolved Cohn Fraction IV-1 Paste; Journal of Chromatography A. 800 (2) (1998): 207-218.					
N	05	HIGHSMITH, F; XUE, H; CHEN, X; BENADE, L; OWENS, J; SHANBROM, E; DROHAN, W; lodine-mediated Inactivation of Lipid- and Nonlipid-enveloped Viruses in Human Antithrombin III Concentrate; Blood, Volume 86, No. 2 (July 18, 1995); pages 791-796					
M	06	HIGHSMITH, FA; XUE, H; CAPLE, M; WALTHALL, B; DROHAN, WN, SHANBROM, E; Inactivation of Lipid-Enveloped and Non-lipid-enveloped Model Viruses in Normal Human Plasma by Crosslinked Starch-iodine; Plasma Derivatives Department, Holland Laboratory, American Red Cross, Rockville, Maryland, and Irvine Scientific Incorporated, Santa Ana, California; received for publication Aug. 26, 1993, revised Nov. 16, 1993 and accepted Nov. 22, 1993; published in Transfusion, 1994; Volume 34, No. 4, pages 322-327.					
W	07	HIGHSMITH, FA; CAPLE, M; WALTHALL, B; SHANBROM, E; DROHAN, WN; Viral Inactivation of Vesicular Stomatitis Virus in Normal Human Serum by Cross-Linked Polyvinylpyrrolidone; <i>The Journal of Infectious Diseases</i> , 1993;167:1027-33, published by The University of Chicago.					
M	08	treated Blood	Proc	lucts; <i>Blood Coagul. Fibr</i>	; WATKLEVICZ,C; Viral Safet inolysis. 1994 Dec; 5 Suppl 3 iral safety in formal clinical tr	3: S21-28. See Abstract	

Examiner Signature	ash	Date Considered	11/15/04	
			7-7-	

Substitute	for fo	rm 1449A/P	TO (Re	plication)	Complete if Known		
		ION DIS			Application Number	10/661,329	
STATEMENT BY APPLICANT				CANT	Filing Date	September 12, 2003	
6	. 4	egg i			First Named Inventor	Allan L. Louderback	
l control of the cont					Art Unit		
1	, 				Examiner Name		
Sheet	NIB	IEAL 3	of	4	Attorney Docket Number	ALL001	
		OTHE	R PRI	OR ART - NON PAT	ENT LITERATURE DO	CUMENTS	
Examiner Initials	#	Include n (book, mag	ame of s gazine, j	ournal, serial, symposium, i	TERS), title of the article (when catalog, etc.), date, page(s), vol or county where published	appropriate, title of the item ume-issue numbers, publisher,	
m	_09	HOROWIT proceeding	Z, B; Pa js pape	athogen Inactivated Trai or from <i>Vox Sanguinis (V</i>	nsfusion Plasma: Existing and Fox Sang 2002: 83, (Suppl.	d Emerging Methods, a 1): 429-436	
m	10	HOROWITZ, B; BEN-HUR, E; Efforts in Minimizing Risk of Viral Transmission through Viral Inactivation; The Finish Medical Society Duodecim, Ann. Med. 2000, 32: 475-484.					
n	11	Solvent/De	tergeni	AZO, A; GROSSBERG, F t Treatment and the Mai r; Vox Sang. 1998, 74,	H; PAGE, G; LIPPIN, A; SWAN, G.; Virus Inactivation by inufacture of SD-Plasma; Vox Sanguinis, Lunch Suppl. 1;: 203-206.		
m	12	HOROWITZ, B; PRINCE, AM; HAMMAN, J; WATKLEVICZ, C; Viral Safety of Solvent/Detergent-treated blood products - ABSTRACT; Dev Biol Stand. 1993;81: 147-161.					
W	13	KORNEYEYA, M; HOTTTA, J; LEBING, W; ROSENTHAL, RS; FRANKS, L; PETTEWAY, SR Jr.; Enveloped Virus Inactivation by Caprylate: a Robust Alternative to Solvent-Detergent Treatment in Plasma Derived Intermediates; <i>Biologicals</i> , 2002 Jun; 30(2): 153-62.					
N	14	LEBING, WR; HAMMOND, DJ; WYDICK, JE III; BAUMBACH, GA; A Highly Purified Antithrombin III Concentrate Prepared from Human Plasma Fraction IV-1 by Affinity Chromatography; Vox Sanguinis, Vox Sang., 1994; 67(2): 117-124.					
w	15	LEBING, W; REMINGTON, KM; SCHREINER, C; PAUL, I; Properties of a New Intravenous Immunoglobulin (IGIV-C, 10%) Produced by Virus Inactivation with Caprylate and Column Chromatography; copyright Blackwell Publishing, Ltd., Vox Sanguinis (2003): 84(3), 193-201.					
M	16	LEE, DC; STENLAND, CJ; MILLER JLC; CAI, K; FORD, EK; GILLIGAN, KJ; HARTWELL, RC; TERRY, JC; RUBENSTEIN, R; FOURNEL, M; PETTEWAY SR Jr.; A Direct Relationship between the Partitioning of the Pathogenic Prion Protein and Transmissible Spongiform Encephalopathy Infectivity during the Purification of Plasma Proteins; <i>Transfusion</i> , 2001: 41(4): 449-455.					
M	77,	LOUDERBA 5 th National GA on Mare	Forum	on AIDS, Hepatitis and	ion of Blood for Transfusion; other Blood Borne Diseases;	Oral presentation at the CDC Meeting, Atlanta,	

Examiner Signature	Jylin	Date Considered	11/18/04

Substitute for form 1449A/PTO (Replication)		m 1449A/P1	O (Re	plication)	Complete if Known			
INFORMATION DISCLOSURE SPATEMENT BY APPLICANT					Application Number	10/661,329		
				CANT	Filing Date	September 12, 2003		
					First Named Inventor	Allan L. Louderback		
					Art Unit			
	TENT	/			Examiner Name			
eet		4	of	4	Attorney Docket Number	ALL001		
		OTHE	R PRI	OR ART - NON P	ATENT LITERATURE DO	CUMENTS		
aminer tials	#	Include n (book, ma	ame of gazine,	journal, serial, symposis	LETTERS), title of the article (wher urn, catalog, etc.), date, page(s), vo and/or county where published	n appropriate, title of the item furne-issue numbers, publisher,		
M	18	LOUDERE	ACK,	A; Sterilization of Rec o, November 11, 199	I Blood Cells for Transfusion; Sp 2.	eech at 45 th AABB Meeting		
N	19	Immunog	MILLER. JLC; PETTEWAY, SR Jr; LEE, DC; Ensuring the Pathogen Safety of Intravenous Immunoglobulin and Other Human Plasma-derived Therapeutic Proteins; Journal of Allergy Clinical Immunology, October 2001 V. 108, pages S91-4 (Figure S92).					
w	20	ROBINSON, S; SCHWINN, H; JOSIC, D; NUR, I; STRADLER, M; BAL, F; GEHRINGER, W; SCHUTZ, R; Development and Biochemical Characterization of a Double-virus-inactivated Factor VIII Preparation, Blood Coegulation and Fibrinolysis, Vol 6, Suppl. 2, 1995, copyrighted by Rapid Science Publishers; pages S40-47.						
n	21	SCHWINN, H; STADLER, M; JOSIC, DJ; BAL, F; GEHRINGER, W; NUR, I; SCHŪTZ, R; A Solvent 1 Detergent Treated, Pasteurised and Highly Purified Factor VIII Concentrate; ArzneimForsch./Drug Res. 44(I), Nr. 2 (1994) pages 188-191 (English and German).						
W	22	STENLAN Human an	STENLAND, CJ; LEE, DC; BROWN, P; PETTEWAY SR Jr.; RUBENSTEIN, R; Partitioning of Human and Sheep Forms of the Pathogenic Prion Protein during the Purification of Therapeutic Proteins from Human Plasma, <i>Transfusion</i> , Volume 42(11), November 2002, pages 1497-					
n	23	Jr.; REMIN	TREJO, SR; HOTTA, JA; LEBING, W; STENLAND, C; STORMS, RE; LEE, DC; PETTEWAY, LS Jr.; REMINGTON, KM; Evaluation of Virus and Prion Reduction in a New Intravenous Immunoglobulin Manufacturing Process; Vox Sanguinis (2003) 84, 176-187, copyrighted by Blackwell Publishing, Ltd.					
N	24	PRINCE, A	M; Blo	od Products; Nature.	1996 Jan 4; 379 (6560):14. S	See entire article		
	25	STORMS,	RB; RL	JBENSTEIN, R; PETEV	GILLIGAN, KJ; HARTWELL, RC; NAY, SR Jr.; LEE, DC; Solvent-c a Acta. 2002 May 20; 1597(1)	lependent Precinitation of		

•

Examiner Signature	Story!	Date Considered	11/18/04	
	0 ()		//	